COVID-19: Centre Waives Import Duty on Remdesivir and Its Raw Materials
The move would help augment domestic availability and reduce cost of the injection.
A consignment of 15,000 Remdesivir injections reach Indore from Karnatakas Bengaluru and for distribution across cities in Madhya Pradesh. Photo: PTI/@CMMadhyaPradesh/Twitter
Trade1 hour ago
New Delhi:Â Amid surging COVID-19 cases in the country, the government on Tuesday waived customs duty on Remdesivir, its raw materials and other components used to make the antiviral drug.
The move would help augment domestic availability and reduce cost of the injection.
Remdesivir is being used in the treatment of coronavirus.
3,029,815.0
The government s decision to waive off customs duty on antiviral drug Remdesivir would help in augmenting the supply of the medicine in the wake of soaring COVID-19 cases in the country, Chemicals and Fertilisers Minister Sadanand Gowda said on Wednesday. The government on Tuesday waived off all customs duty on imported Remdesivir injections and the drug s active pharmaceutical ingredients (API) in order to boost supplies. There is already a ban on the export of the Remdesivir injection from the country. Considering the immediate requirement on the recommendation of the Department of Pharmaceuticals, the Department of Revenue has reduced customs duty on #Remdesivir and its API/KSM. This step will further augment domestic availability of Remdesivir injection, Gowda said in a tweet.
Export of Remdesivir has been prohibited on 11th April in order to shore up domestic supplies : Ministry
New Delhi:
Amid reports of shortage of antiviral drug Remdesivir, the centre on Wednesday announced that the production capacity of Remdesivir injections is being ramped up from the current level of 38 lakh vials per month to 74 lakh vials per month.
It also said that 20 additional manufacturing sites have been approved.
The Union health ministry in coordination with the Department of Pharmaceuticals has made an interim allocation of Remdesivir for 19 states and Union territories (UTs) for the period up to April 30, to further address reports of shortage of the drug in certain regions of the country and facilitate its smooth inter-state supply.
Manufacturers have been directed to manufacture and dispatch the supplies as per the agreed state allocation and mapping. They may be asked to balance supplies to the government and distribution channels.
Also, interim allocation of the key
It is for states like Chhattisgarh, Delhi, Gujarat, Haryana, Andhra Pradesh, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Punjab, Rajasthan, Tamil Nadu, Uttar Pradesh, Uttarakhand, Telangana, West Bengal, Odisha, Bihar and Jharkhand.
States not covered by the above-mentioned allocation will be considered for allocation when their supply orders are placed with the manufacturers.
A Control Room set up by National Pharmaceutical Pricing Authority (NPPA) shall be responsible for monitoring the operations as per the allocations. A Whatsapp group comprising nodal officers of states to coordinate unhindered movement of Remdesivir within the country is also being created.
The Minister had earlier asked the State governments to take strict action against anyone found indulged in black marketing or hoarding of Remdesivir.
The government’s decision to waive off customs duty on antiviral drug Remdesivir would help in augmenting the supply of the medicine in the wake of soaring COVID-19 cases in the country, Chemicals and Fertilizers Minister Sadananda Gowda said on Wednesday.
The government on Tuesday waived off all customs duty on imported Remdesivir injections and the drug’s active pharmaceutical ingredients (API) in order to boost supplies.
There is already a ban on the export of the Remdesivir injection from the country. “Considering the immediate requirement on the recommendation of the Department of Pharmaceuticals, the Department of Revenue has reduced customs duty on #Remdesivir and its API/KSM. This step will further augment domestic availability of Remdesivir injection,” Mr. Gowda said in a tweet.